FORT LEE, N.J.--(BUSINESS WIRE)--Nov. 18, 2005--Neurologix, Inc. (OTCBB: NRGX) today announced findings from preclinical studies, which showed that the gene XIAP (X-linked inhibitor of apoptosis) may prevent the progression of Huntington’s disease. Neurologix scientists demonstrated that a mutated form of the gene delivered by an adeno-associated virus (AAV) vector, introduced using standard neurosurgical techniques can improve motor deficits associated with the disease. Huntington’s disease is a fatal neurological genetic disorder characterized by debilitating movement abnormalities, for which there is currently no effective treatment available. The findings were presented in a poster session during the 35th Annual Meeting of the Society for Neuroscience in Washington D.C. by Sergei A. Musatov, Susan E. Browne, Matthew S. Henning, Mihaela A. Stavarache, Joshua A. Goldfein, and Michael G. Kaplitt. The title of the poster was “Neuroprotective effects of XIAP in models of Huntington’s disease.”